Aleix Prat: Which biomarker predicts best OS in early stage TNBC?
Aleix Prat, Director of the Cancer Institute at the Hospital Clinic of Barcelona, shared on LinkedIn:
“Which biomarker predicts best overall survival in early stage TNBC?
238 patients from CALGB40603 and 380 patients for validation
1,037 DNA somatic mutations
534 DNA copy number aberratioms
759 RNA expression signatures
Clear answer: RNA! and in particular the Bcell IGG signature is the one with the most weight together with tumor stage! DNA does not offer value for this objective
Great work!”
Aleix Prat is the Director of the Cancer Institute at the Hospital Clinic of Barcelona, Head of the Translational Genomics Group at IDIBAPS, and a Professor at the University of Barcelona.
He is also a Co-Founder of REVEAL GENOMICS, S.L. His work focuses on breast cancer genomics and the development of omics-based assays for clinical application. His expertise lies in breast cancer and gene expression profiling.
Further Reading:
Highlights from Day 1 of SABCS 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023